A randomized trial comparing empirical and guide therapy for unexplained non-cardiac chest pain by Kadir, Noor Purdah Abdul
  
A Randomized Trial Comparing Empirical and Guided Therapy for 









Dissertation Submitted In Partial Fulfilment of The requirement for 
The Degree of Master of Medicine 
(Internal Medicine) 
 












In the name of Almighty God,immeasurable appreciation and deepest gratitute for the help 
and support are extend to the following persons who in one way or another have contributed 
in making this study possible. 
 
My dissertation advisor Professor Dr Lee Yeong Yeh of the medical department at Hospital 
Universiti Sains Malaysia. I am grateful to him, whose expertise, understanding, generous 
guidance and support made it possible for me to work on a topic that was of great interest to 
me. It was a pleasure working with him. 
 
Dr Hady lecturer of Internal Medicine, Hospital Universiti Sains Malaysia, and thesis 
committee. My sincere thanks to him for provided me an opportunity for the research grant 
and others facilities. Without his precious support it would not be possible to conduct this 
research. 
Special thanks to Professor Syed Hatim Noor for his professional advice and helping me to 
prepare and reviewing my study sample and statistical analysis.  
 
I would also like to thank the experts who were involved in the validation survey for this 
dissertation project Puan Nurhazwani,Dr Muhammad Ilham, Dr Chandra and SN Hasliza. 





 Professor Dato Dr Zurkurnai Yusof, Head of Department of Internal Medicine, School of 
Medical Sciences, Universiti Sains Malaysia (USM), thank for his support, during the 
completion of this dissertation. 
 
Last but not least, my beloved husband Mohammad Sharul Mizan Md Isa, my precious 
parents Abdul Kadir Yusoff and Saadiah Hamzah,I must express my very profound gratitude 
to them for providing me with unfailing support and continuous encouragement throughout 
my years of study and through the process of researching and writing this thesis. This 
accomplishment would not have been possible without them. 
 
Thank you. 


















TABLE OF CONTENTS 
CONTENTS                                                                                                  PAGE NUMBER 
List of tables and figures                                                                                               6,7                     
List of abbreviations                                                                                                       8 
Abstract                    in English                                                                                                         
9,10 
Abstrak                  ct in Malay                                                                                                           
11,12 
                                                                                                                                                                                                                                                                   
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1.1 Background of study and literature review                                                            141-
,162                                                                                                     
1.2 Definition and epidemiology of non-cardiac chest pain                                         17,183                             
1.3 Pathophysiology and mechanism of non-cardiac chest pain                                 184-
2016 
1.4 The use of high resolution manometry and PH study as a diagnostic tool.          2117                        
1.5 Treatment of non-cardiac chest pain                                                                                
1.5.1 GERD related NCCP                                                                                 
22,2318,19 
            1.5.2 Non-GERD related NCCP                                                                        2319-
251            
5 
 
CHAPTER 2: OBJECTIVES    
2.1 General objectives                                                                                                     273 
2.2 Specific objectives                                                                                                     273 
CHAPTER 3: METHOD                                                                                               295                                                
3.1 Study design     
3.2 Sample size calculation       
3.3 Hypothesis                                                                                      
3.4 Study population and methods 
            3.4.1 Inclusion and exclusion criteria                                                                
30,3126       
3.4.2 Randomization                                                                      
3127,3228 
3.4.3 Research Tools 
        3.4.3a Visual analogue scale (VAS)                                                           3329 
        3.4.3b QOLRAD                                                                                          340 
        3.4.3c GERDQ                                                                                             340 
        3.4.3d High resolution oesophageal manometry                                      35,361 
        3.4.3e 24 hour ambulatory pH-impedance monitoring                           37,382           
3.5 Intervention                                                                                                              394 
       3.5.1 Empirical Group 
       3.5.2 Guided Group     
3.6 Data and statistical analysis                                                                                     4035 
3.7 Ethical issue                                                                                                              4136      
CHAPTER 4: RESULTS    
6 
 
 4.1: Descriptive analysis                                                                                                45-53 
   CHAPTER 5: STATISTICAL ANALYSIS                                                                                            
40-47 
54.12: Independent T test analysis                                                                                   
55,5648,49 
54.23: Paired t test analysis                                                                                               57-
620-55 
54.34: Repeated measures analysis of variance (RMANOVA)                                      63-
6756-60 
 54.45: Simple linear regression and multiple linear regression analysis                     
68,691-62 
CHAPTER 65: DISCUSSION                                                                                        70-
7865-71                           
CHAPTER 76: CONCLUSION           
80,8173-74 
CHAPTER 87: STUDY LIMITATION AND RECOMMENDATION                     
83,8476-77 
CHAPTER 98: REFERENCES                                                                                     86-
8979-82 








List of tables and figures 
Figure 1        Anatomical relation of heart and esophagus 
Figure 2        Los Angeles classification of esophagitis 
Figure 3       Visual Analogue Scale 
Figure 4       Chicago classification for esophageal motor dysfunction 
Figure 5       24 hour esophageal monitoring showing position of probe in relation with LES 
Figure 6       High resolution manometry 
Figure 7       Impedance catheter 
Figure 8       pH probe and pH recorder 
Figure 9       Flow chart of research activity. 
 
Table 4.1.0:  Adverse Events 
Table 4.1.1: Characteristics study of participants for Guided therapy (n=25) and Empirical 
therapy (n=21). 
 
Table 4.1.2a: Descriptive data of manometry and 24 hour pH study for Guided therapy 
(n=25) and Empirical therapy (n=21). 
 
Table 4.1.2b: Table of mean  pressure  metrics of manometry for guided and empirical 
groups. 
 
Table 4.1.3: The mean of QOLRAD dimensions for week 0, 2 and 8 for guided group and 
empirical group. 
 
Table 54.12.1: The mean difference of VAS, GERDQ and QOLRAD scores of guided group 
versus empirical group . 
 
Table 54.23.1a: : Characteristics of VAS, GERDQ and QOLRAD scores in guided  group 
(week 0 - week 2). 
 
Table 54.23.1b:  Characteristics of VAS, GERDQ and QOLRAD scores in guided  group  
( week 0 - week 8). 
 
Table 54.23.1c:  Characteristics of VAS, GERDQ and QOLRAD scores in guided  group 
8 
 
( week 2 - week 8). 
  
Table 54.23.2a: Characteristics of VAS, GERDQ and QOLRAD scores in empirical  
group(week 0- week 2). 
 
Table 54.23.2b: Characteristics of VAS, GERDQ and QOLRAD scores in empirical  
group(week 0- week 8). 
 
Table 54.23.2c: Characteristics of VAS, GERDQ and QOLRAD scores in empirical  
group(week 2- week 8). 
 
Table 54.34.1: Within group difference (VAS) .  
 
Table 54.34.2: Within group difference (GERDQ). 
 
Table 54.34.3: Within group difference (QOLRAD). 
 
Table 5.4.34.4: Between groups differences (VAS, GERDQ, QOLRAD). 
 
Table 54.34.5: Within-between groups differences. 
 
Table 54.45.1: Simple linear regression for factor associated with VAS at week 8 in guided 
group (n=25). 
 
















List of abbreviations 
BMI                      Body mass index    
FDA                     Food and Drugs Administration 
GERD                  Gastroesophageal Reflux Disease 
GERDQ               Gastroesophageal Reflux Disease Questionnaire 
HRM                    High Resolution Manometry 
LES                      Lower Esophageal Sphincter  
NCCP                  Non Cardiac Chest Pain 
OTC                     Over the Counter 
PPI                       Proton Pump Inhibitor 
QOLRAD            Quality of Life Reflux and Dyspepsia 
RM-ANOVA        Repeated measures analysis of variance 
USM                    Universiti Sains Malaysia 














ABSTRACT IN ENGLISH 
 
Background Non-cardiac chest pain (NCCP) is prevalent in Malaysia with almost two-thirds 
a result of gastroesophageal reflux disease. Treatment approach to NCCP is currently unclear. 
We aimed to determine if therapy guided by results of 24-hour pH-impedance test would be 
better than empirical trial of PPI.  
 
Methods Consecutive participants with chest pain and normal angiogram or negative stress 
test were consented. Participants were randomized into guided group or empirical group. In 
guided group, all underwent 24-hour pH-impedance test (Sandhills, US) and if GERD then 
eight weeks of Dexlansoprazole 30mg OD but if functional chest pain or reflux 
hypersensitivity then four weeks of Theophylline SR 250mg OD were prescribed. In 
empirical group, two weeks of Dexlansoprazole 60mg OD were prescribed. Visual analog 
scale assessment (VAS) of chest pain, Gastroesophageal Reflux Disease Questionnaire 
(GERD Q), and Quality Of Life in Reflux And Dyspepsia (QOLRAD) questionnaire were 
evaluated during each visits at weeks 0, 2 and 8. Differences between visits were analyzed 
with Repeated Measures ANOVA. 
 
Results Of 200 screened patients, 145 did not meet inclusion criteria, and 55 randomized (26 
empirical and 29 guided). A further 9 withdrew (5 empirical and 4 guided). No participants 
experienced serious adverse events. With RM-ANOVA, the results demonstrated that guided 
therapy did better than empirical therapy in mean VAS at week 2 vs. 0 and at week 8 vs. 0. 
The mean values of guided group were outside the confidence intervals of empirical group. 
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Therefore, the mean VAS were significantly different. The results also demonstrated 
significant improvement of mean QOLRAD at week 8 vs. 0 in the guided therapy with  
p value=0.007, MD (95%CI) -3.2(-5.7,-0.8).However, no significant improvement in GERD 
Q were observed.In within-group analysis, mean QOLRAD was significantly better at week 8 
vs. 0 (P=0.007) for guided group and for empirical group, mean QOLRAD was better at 
week 2 vs. 0 (P=0.004) and week 8 vs. 0 (P=0.01). On the other hand, mean GERDQ was 
better at week 8 vs. 0 (P=0.02) for empirical group only. We also observed that duration of 
treatment was the factor associated in the improvement of VAS in guided group. A duration 
of one week treatment would result in reduction of VAS scores by 0.7 points (95% CI -1.2, -
0.2; p=0.007). 
 
Conclusion In this  analysis, guided therapy seems better than PPI trial in relieving chest pain 
symptom of NCCP patients. Both therapies improved QOL but those with GERD symptoms 










ABSTRAKCT IN MALAY 
 
Latar belakang kajian:Sakit dada bukan berpunca jantung di  Malaysia lazimnya dua per 
tiga berpunca  daripada penyakit refluks gastroesofagus.Perawatan  untuk sakit dada bukan 
berpunca jantung buat masa ini masih kurang jelas.Kajian ini bertujuaan membandingkan jika 
perawatan berpanduan berdasarkan keputusan ujian 24 jam PH impedance lebih baik 
daripada  perawatan empirical dengan percubaan PPI. 
 
Metodologi:Penyertaan adalah  daripada pesakit yang mempunyai sakit dada tetapi 
keputusan angiogram normal atau ujian tekanan larian jantung negative yang 
bersetuju.Peserta dirawakan kepada dua kumpulan iaitu perawatan berpanduan dan perawatan 
empirical.Di dalam kumpulan perawatan berpanduan,kesemua peserta melalui ujian 24 jam 
PH impedance (Sandhills, US).Berdasarkan keputusan ujian ini,jika sakit dada bukan 
berpunca jantung adalah disebabkan oleh penyakit refluks gastroesofagus,Tablet 
Dexlansoprazole 30 mg sekali sehari dipreskripsi untuk tempoh 8 minggu.Manakala jika ia 
berpunca daripada penyakit refluks esofagus hipersensitif, tablet Theophylline SR 250 mg 
sehari sekali dipreskripsi untuk tempoh 4 minggu.Untuk peserta didalam kumpulan 
perawatan empirical,tablet Dexlansoprazole 60 mg sehari sekali dipreskripsi untuk tempoh 2 
minggu.Seterusnya, skor tahap kesakitan sakit dada (VAS), soalselidik penyakit refluks 
gastroesofagus (GERD Q) dan soalselidik kualiti hidup pesakit refluks dan dispepsia 
(QOLRAD) dinilai pada setiap lawatan pada minggu 0, 2 dan 8.Perbezaan disetiap lawatan 




Keputusan: 200 pesakit sakit dada bukan berpunca jantung dinilai.145 tidak memenuhi 
kriteria.55 peserta memenuhi kriteria dan dirawakan kepada dua kumpulan iaitu 26 didalam  
kumpulan perawatan empirikan dan 29 didalam  kumpulan perawatan berpanduan.Seterusnya 
5 peserta daripada perawatan empirikal  dan 4 peserta daripada perawatan berpanduan 
digugurkan daripada kajian.Tiada peserta mengalami komplikasi akut didalam kajian 
ini.Dengan RM-ANOVA,keputusan menunjukkan perawatan berpanduan mempunyai 
tindakbalas yang lebih baik berbanding perawatan empirical didalam purata VAS pada 
minggu ke 2 berbanding minggu 0 dan  pada minggu 8 berbanding minggu 0.Keputusan juga 
menunjukkan  purata kemajuan didalam QOLRAD pada minggu ke 8 berbanding minggu 0 
(p =0.007, MD (95%CI) -3.2(-5.7,-0.8) didalam kumpulan perawatan 
berpanduan.Walaubagaimanapun,tiada purata kemajuan dilihat untuk soalselidik GERD 
Q.Analisa didalam kumpulan berpanduan menunjukan purata QOLRAD lebih baik pada 
minggu ke 8 berbanding minggu 0 (p=0.007).Manakala didalam kumpulan perawatan 
empirical purata QOLRAD dilihat lebih baik pada minggu ke 2 berbanding 0( p=0.004) dan 
pada minggu ke 8 berbanding minggu 0 (p=0.01).Untuk analisa didalam kumpulan, purata 
GERD Q hanya dilihat lebih baik di dalam kumpulan perawatan empirical pada minggu  ke 8 
berbanding minggu 0(p=0.02).Tempoh rawatan juga dilihat memainkan peranan dalam 
kesembuhan sakit dada didalam kumpulan perawatan berpanduan.Penambahan sebanyak 
seminggu tempoh rawatan,membolehkan pengurangan skor VAS sebanyak 0.7%(95% CI -
1.2, -0.2; p=0.007). 
 
Kesimpulan: Di dalam analisa ini,perawatan berpanduan dilihat lebih baik berbanding 
percubaan PPI dalam mengurangkan simptom sakit dada pesakit sakit dada bukan berpunca 
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jantung(NCCP).Kedua-dua rawatan meningkatkan kualiti hidup pesakit,tetapi simptom 























CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
1.1 BACKGROUND OF STUDY AND LITERATURE REVIEW 
 
Non-cardiac chest pain (NCCP) is very common in the general population but symptom 
alone or patient’s characteristics do not adequately differentiate cardiac and esophageal 
causes [1]. Cardiologists are usually consulted first to exclude life-threatening acute 
coronary syndrome. Tests that are performed to exclude ischemic heart disease include 
exercise stress test and the more invasive coronary angiography. A negative stress test or 
angiogram or the presence of mild blockage of a single vessel disease will usually be 
adequate to exclude significant ischemia as a cause for chest pain. 
 
The next most important cause of unexplained chest pain would be gastro-esophageal 
reflux disease (GERD). GERD and its complications of Barrett’s oesophagus and 
oesophageal adenocarcinoma have increased markedly in recent decades, not just in the 
developed countries but also in Asia [2]. Although relatively less common among 
populations in Malaysia [3], there are data to suggest an increasing prevalence of reflux 




Numerous studies have shown the association between NCCP and GERD. There is 
approximately 37 to 61.5% of patients with NCCP have experienced GERD symptoms 
[6–8].Likewise, half of patients with NCCP have abnormal ambulatory 24-hour pH 
studies [9,10].Only one study from Asia has shown that 34.3% of patients with NCCP 
have at least 1 abnormal pH parameter [11]. 
 Functional chest pain due to esophageal hypersensitivity is the next common cause for 
unexplained NCCP [12, 13]. Only a minority of patients with NCCP have esophageal 
dysmotility disorders that include nutcracker esophagus, diffuse esophageal spasm and 
achalasia [1]. 
 
It is unknown what would be the next recommended approach once cardiac causes of 
chest pain are excluded. A proton-pump inhibitor (PPI) test may be tried and has been 
found to be effective in 60 to 90% of patients [14–16]. The wide range in response may 
be attributed to heterogeneity of study population and differences in the dose and types 
of PPI used. Cytochrome CYP2C19 polymorphisms may affect metabolism of PPI and 
those who are “poor metabolizers” particularly among Asians may experience more 
adverse effects. However among the Malays poor metabolizers are reported in only 
5.6% compared to 19.1% among the Chinese [17]. 
 
 Dexlansoprazole (Takeda Pharmaceuticals, Japan) is a novel dual delayed release 
system recently approved by the FDA for treatment of heartburn associated with non-
erosive and erosive reflux disease [18]. It is unknown if dexlansoprazole is effective as 




Another approach would be therapy guided by investigations including high resolution 
(HR) esophageal impedance manometry and 24-hour pH-impedance studies. Study of 
esophageal function has greatly evolved with the recent availability of high resolution 
multi-channel solid state manometer and impedance [19]. Water swallows are 
commonly used in esophageal manometric studies to evaluate for peristaltic 
abnormalities. Esophageal pH monitoring does not detect all gastroesophageal reflux 
(GER) events but with the combination of impedance, this technique allows detection of 
GER of gas and acid or non-acid liquids [20]. These tests would enable diagnosis of 
GERD and functional chest pain and thereby allow targeted therapy.  
 
For treatment of GERD, dexlansoprazole is effective [21] and for functional chest pain, 
nonspecific adenosine antagonist, theophylline is proven to improve symptoms in 
patient with hypersensitive esophagus [22]. A selective serotonin reuptake inhibitor 
(SSRI) is also effective for functional chest pain [23], however it is not known if 
theophylline is more effective than any other SSRIs.It is unknown about the response 
rates based on the guided therapy approach compared to the empirical PPI therapy and 















1.2 DEFINITION AND EPIDEMIOLOGY OF NON CARDIAC CHEST PAIN 
 
Non cardiac chest pain is defined as recurrent chest pain is indistinguishable from 
ischemic heart pain after a reasonable workup has excluded a cardiac cause. (Fass & 
Achem, J Neurogastroenterol Motil 2011; 17:110-123). 
 It is significantly resulting in high healthcare utilization and significant work 
absenteeism. However, despite its chronic nature, non-cardiac chest pain has no 
impact on patients’ mortality.  
The main underlying mechanisms include gastroesophageal reflux, esophageal 
dysmotility and esophageal hypersensitivity. 
NCCP is common in Asia but information about the epidemiology of NCCP in the 
Asia and around the world is relatively limited. The mean annual prevalence of NCCP 
in 6 population based studies was approximately 25%. However, these studies differ 
in many aspects such as NCCP definition, geography, sample size, sampling order 
and ethnic disparities. 
In the United States assessed the prevalence of GERD in Olmsted County, Minnesota 
and reported an overall NCCP prevalence of 23%. Gender distribution among NCCP 
patients was similar (24% among males and 22% among females). 
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A nationwide population-based study from South America found that the annual 
prevalence of NCCP was 23.5% and that NCCP has been equally reported by both 
sexes. 
Another epidemiologic study demonstrated that the annual prevalence of NCCP in a 
Chinese population was 19%.In Asia population reported that 66.7% of NCCP 
prevalence is due to gastroesphageal reflux (Hanizam Mohd, 2008). 
NCCP patient in comparison with cardiac origin chest pain patient are more younger 
in view of  they are consume greater amount of alcohol, smoke more often, and more 
likely suffer from anxiety which attribute to NCCP.  
These prove by several studies which shown a decrease in the prevalence of NCCP 
with increasing age (Chiocca JC,Olmos JA,2005). 
 
 
1.3 PATHOPHYSIOLOGY AND MECHANISM OF NON CARDIAC CHEST 
PAIN 
 
Pathophysiology of non-cardiac chest pain is remains to be fully unclear. It may be 
attributed to multiple gastrointestinal, musculoskeletal, pulmonary and psychological 
causes (Leise et al., 2010). Esophageal disorders can also be the etiology of chest pain 
(Lemme, Moraes-Filho,Domingues, Firman, & Pantoja, 2000). Gastroesophageal 
reflux disease (GERD) is the main underlying mechanism of NCCP, accounting for 
up to 60 % of cases (Leise et al., 2010). NCCP can also be caused by esophageal 
motor dysfunction; and the frequency may be underestimated. Motor disorders are 
observed in almost 50% of patients with NCCP who ultimately undergo conventional 
manometry evaluation (Gambitta et al., 1999). 
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The close anatomical relationship between the esophagus and the heart contributes to 
the similarity in symptoms and the difficulty in distinguishing the origin of chest pain 
(Figure1).  
The esophagus is located posterior to the heart and is separated from the left atrium by 
the pericardium. Both the heart and the esophagus share the same common path of 
pain fibers from the sympathetic trunk (Heatley, Rose & Weston, 2005). 
Esophageal pain has many patterns. Patients usually describe it as burning, gripping, 
stabbing, and pressing in the anterior chest. The pain is also usually in the throat or 
epigastrium and sometimes radiates to the neck, back or upper arms. These symptoms 
may also apply to cardiac pain (Bennett, 2001). 
The specific mechanisms for esophageal-induced NCCP are poorly understood (Fang 
& Bjorkman, 2001).The potential for an esophageal etiology for recurring NCCP was 
originally hypothesized by William Osler in 1892 (Castell, Talley, & Travis, 2010).  
For GERD, it is widely understood that the characteristic pain  is burning  epigastric, 
and related to recent food intake, lying down or bending (Bennett, 2001).Pain as a 
result of esophageal spasms is retrosternal, deep and often labeled as burning, 
squeezing or aching, usually radiating to the arms, jaw, and back (Heatley, Rose & 
Weston,2004). 
However, a few possible mechanisms have been identified and include: irritant stimuli 
to the esophageal mucosa, mechanical effects on the muscular wall, and visceral 
hypersensitivity (Castell et al., 2010). 
 
1.3a: Mucosal stimulation. 
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Chest pain arises from esophageal mucosal irritation by acid exposure. This causes 






1.3b: Mechanical changes. 
 Alterations in esophageal motility can be a cause of chest pain. This includes 
achalasia (absent distal peristalsis or abnormal relaxation of the LES), diffuse 
esophageal spasm (DES) (simultaneous contractions or intermittent peristalsis), 
nutcracker esophagus (increased contraction amplitude of over 180 mm Hg with 
normal peristalsis), hypotensive LES, and ineffective esophageal motility 
(contractions of low amplitude or failed and non-transmitted) (Bennett, 2001). 
 
1.3c: Visceral hypersensitivity 
Chest pain caused by alterations in visceral receptor sensitivity; the prevalence is 







Figure1: Anatomical relation of heart and esophagus (Adopted from American 





1.4  THE USE OF HIGH RESOLUTION MANOMETRY AND PH STUDY AS A 
DIAGNOSTIC TOOL 
 
High resolution manometry is a new technology used to measure intraluminal pressure 
activity within the gastrointestinal tract using a series of closely spaced pressure sensors 
within the esophagus. It uses a series of 36 1-cm-spaced pressure sensors that provides 
detailed pressure information that reveals the segmental nature of esophageal peristalsis. 
(Parkman, McCallum, &Rao, 2011, p. 22). 
Esophageal manometry combined with acid perfusion has been found to be a safe and   
reliable technique for the diagnosis of patients with NCCP since 1991.In 2003 Lacima, 
Grande, Pera, Francino, and Ros  found that ambulatory manometry had a small but perhaps 
important impact on the diagnosis of   patient with NCCP compared to standard esophageal 
testing. However this study using conventional manometry but recent study by Hilal Imam 
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2012 prove that the use of HRM has changed the diagnostic approach to esophageal motility   
disorders. 
 It is the most specific and sensitive test for diagnosing motor disorders and a promising 








1.5 TREATMENT FOR NONCARDIAC CHEST PAIN 
 
1.5.1  GERD RELATED NCCP 
 
1.5.1a: Lifestyle Modifications 
Lifestyle modifications like elevated of head of the bed, weight loss, cessation of 
smoking, avoidant of alcohol, caffeine, fresh citrus juice and other associated food 
products as well as few medication which can exacerbate reflux are commonly 
recommended to patient with GERD. However, at the moment there was no proven 
data to support their efficiency in treating patient with GERD related NCCP. 
 
1.5.1b: Histamine-2 Receptor Antagonist (H2RAs) 
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Efficacy of H2RAs in controlling symptoms of patient with GERD related NCCP 
only showed around 42%, thus more potent agent like PPIs needed. 
 
1.5.1c: Proton Pump Inhibitors (PPIs) 
Base on few studies, it was recommended that in treating patient with GERD related 
NCCP, PPIs dose need to double than usual and to be continue until symptoms remit. 
Than followed by tapering dose until the lowest dose that can control the symptoms. 
NCCP patient may require long term treatment beyond 2 months for optimal 
symptoms control. Among all of PPIs, omeprazole has been the most frequently 
studied in clinical trial of GERD related NCCP. 
 
 
            1.5.1d Surgical Treatment 
There are no studies of GERD related NCCP as a sole indication for surgical 
treatment. But there are a few studies in NCCP with symptoms correlation with reflux 
events at least 40% on pH study demonstrated better symptoms improvement after 
complete or partial fundoplication. 
 
1.5.2 NON-GERD RELATED NCCP 
The treatment for non GERD related NCCP is basically base on esophageal pain 
modulation. There for it is important to identify specific motor dysfunction by 
manometry test as specific treatment can be targeted. 
 
1.5.2a: MUSCLE RELAXANTS 
